Education
About Us
Working with TipRanks
Follow Us
Eterna Therapeutics Inc. (ERNA)
:ERNA
ERNA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.75 - $34.35
Previous Close$0.34
Volume440.10K
Average Volume (3M)95.06K
Market Cap
$14.58M
Enterprise Value$15.39M
Total Cash (Recent Filing)$1.92M
Total Debt (Recent Filing)$2.88M
Price to Earnings (P/E)―
Beta1.12
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.21
Shares Outstanding7,361,201
10 Day Avg. Volume37,876
30 Day Avg. Volume95,057
Financial Highlights & Ratios
PEG Ratio-0.16
Price to Book (P/B)-17.58
Price to Sales (P/S)0.00
P/FCF Ratio-1.00
Enterprise Value/Market Cap1.06
Enterprise Value/Revenue8.20
Enterprise Value/Gross Profit30.78
Enterprise Value/Ebitda-0.12
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Eterna Therapeutics News
PremiumCompany Announcements
Eterna Therapeutics Implements 1-for-15 Reverse Stock Split
PremiumCompany Announcements
Eterna Therapeutics Completes $6M Private PlacementOptions Prices
Currently, No data available
---
Ownership Overview
32.72% Insiders
0.45% Mutual Funds
0.76% Other Institutional Investors
66.00% Public Companies and
Individual Investors
ERNA FAQ
What was Eterna Therapeutics Inc.’s price range in the past 12 months?
Eterna Therapeutics Inc. lowest stock price was $1.75 and its highest was $34.35 in the past 12 months.
What is Eterna Therapeutics Inc.’s market cap?
Eterna Therapeutics Inc.’s market cap is $14.58M.
When is Eterna Therapeutics Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Eterna Therapeutics Inc.’s earnings last quarter?
Currently, no data Available
Is Eterna Therapeutics Inc. overvalued?
According to Wall Street analysts Eterna Therapeutics Inc.’s price is currently Overvalued.
Does Eterna Therapeutics Inc. pay dividends?
Eterna Therapeutics Inc. does not currently pay dividends.
What is Eterna Therapeutics Inc.’s EPS estimate?
Eterna Therapeutics Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Eterna Therapeutics Inc. have?
Eterna Therapeutics Inc. has 7,361,201 shares outstanding.
What happened to Eterna Therapeutics Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Eterna Therapeutics Inc.?
Currently, no hedge funds are holding shares in ERNA
Eterna Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Insider Transactions
Bought Shares
Worth $2.1M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-93.80%
12-Months-Change
Fundamentals
Return on Equity
-2264.31%
Trailing 12-Months
Asset Growth
-89.81%
Trailing 12-Months
Company Description
Eterna Therapeutics Inc.
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.
Technical Analysis
Plus Therapeutics
―
Minerva Neurosciences
―
Affimed
―
GeoVax Labs
―
Addex Therapeutics
―